Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504

Mol Cancer, 2014, 15:30

PubMed: 24927996

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed:

Oncotarget, 2015, 51: S659-S660

PubMed:

Julius Maximilians Universit, 2014, Kumari G

PubMed:

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	NULJdWpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMECwN\|A{KM7:TR?=	MXnTRW5ITVJ?
IST-MEL1	NUe0NppzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMECwOFA4KM7:TR?=	M136UXNCVkeHUh?=
NCI-SNU-1	NXza[oNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHMTWM2OD1yLkCwNlA4KM7:TR?=	MmnDV2FPT0WU
FADU	NFTINWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUftOGcxUUN3ME2wMlAxOjB7IN88US=>	NYjTdWY5W0GQR1XS
C32	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVuxdYZ[UUN3ME2wMlAxOzB2IN88US=>	MVnTRW5ITVJ?
D-566MG	NUG2c3doT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnH2TWM2OD1yLkCwN\|kh\|ryP	MnXVV2FPT0WU
LXF-289	NYjnc3BCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGW2cmhKSzVyPUCuNFA1OTlizszN	NWn5NZpYW0GQR1XS
HGC-27	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;qTWM2OD1yLkCwOVEh\|ryP	M3O5UHNCVkeHUh?=
RPMI-7951	Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXmfnJKSzVyPUCuNFA4OTdizszN	MV7TRW5ITVJ?
HSC-3	NH3ISJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLEXWxrUUN3ME2wMlAxQTJ7IN88US=>	M4PLSXNCVkeHUh?=
MIA-PaCa-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnywTWM2OD1yLkCxNFA6KM7:TR?=	MknXV2FPT0WU
KS-1	NXTCVoRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4W1VWlEPTB;MD6wNVM2PSEQvF2=	M3jjNHNCVkeHUh?=
CAL-51	MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTlZ\|c4UUN3ME2wMlAyPDB3IN88US=>	MV\TRW5ITVJ?
MDA-MB-361	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEG0PVUh\|ryP	MnnxV2FPT0WU
TI-73	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfuOldKSzVyPUCuNFE4QTZizszN	NH[0XpVUSU6JRWK=
AGS	NVvoNoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfpXm5KSzVyPUCuNFE6OzhizszN	NF7xbY5USU6JRWK=
NCI-H460	NHnsdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEG5O\|Qh\|ryP	MWXTRW5ITVJ?
A204	NGrvXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjwNmNKSzVyPUCuNFIzPDlizszN	M1LHXXNCVkeHUh?=
CHL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPJWHp2UUN3ME2wMlAzOjVzIN88US=>	M1jlW3NCVkeHUh?=
DU-4475	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\ENXk4UUN3ME2wMlAzOjZzIN88US=>	Mn\lV2FPT0WU
CGTH-W-1	NFzBeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\rTWM2OD1yLkCyN\|Q6KM7:TR?=	MorMV2FPT0WU
HCC2218	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4O5fGlEPTB;MD6wNlQ6PCEQvF2=	NIOx[YVUSU6JRWK=
A2780	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEK1N\|Eh\|ryP	M3;jVXNCVkeHUh?=
NCI-H720	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHmTWM2OD1yLkCyOVQ3KM7:TR?=	NVPIR\|lMW0GQR1XS
NCI-N87	NU\WTJlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEK1PVMh\|ryP	MX\TRW5ITVJ?
CHP-212	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnLU3N3UUN3ME2wMlAzPjJ6IN88US=>	MXPTRW5ITVJ?
NCI-H23	NGHFRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEK2OlUh\|ryP	NVrhcWhTW0GQR1XS
D-263MG	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvsNZlKSzVyPUCuNFI4QDZizszN	NWPLSpU3W0GQR1XS
ME-180	M1nOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;lNGlEPTB;MD6wNlg6OSEQvF2=	NUXyXJJ6W0GQR1XS
SW982	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEK5PVkh\|ryP	MXrTRW5ITVJ?
OE19	NUTC[XhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMEOwO\|ch\|ryP	NGDDOZlUSU6JRWK=
SK-LU-1	M1nTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7zSHpKSzVyPUCuNFMxQDJizszN	MUDTRW5ITVJ?
H4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrmXm92UUN3ME2wMlA{ODlizszN	M1:0XXNCVkeHUh?=
HT-144	NFT4NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPyUYN7UUN3ME2wMlA{ODl\|IN88US=>	M{PHPXNCVkeHUh?=
SK-UT-1	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMEOxO\|gh\|ryP	M4XmbHNCVkeHUh?=
D-336MG	M2rsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[4T3MzUUN3ME2wMlA{OzB7IN88US=>	Mn[wV2FPT0WU
MDA-MB-175-VII	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;JeZRKSzVyPUCuNFM{PTRizszN	MUjTRW5ITVJ?
GAMG	NHzvU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnZOmdyUUN3ME2wMlA{PDN3IN88US=>	NUfqfJI2W0GQR1XS
CP50-MEL-B	NUC5eYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\qV2lEPTB;MD6wN\|Q2KM7:TR?=	NXrxW\|IxW0GQR1XS
OVCAR-5	NWq5b\|ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnG[IFKSzVyPUCuNFM1QCEQvF2=	NWLPXXg5W0GQR1XS
SK-MES-1	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHM[I9XUUN3ME2wMlA{PjB4IN88US=>	NUnv[JB{W0GQR1XS
VM-CUB-1	NH3uTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7xTWM2OD1yLkCzOlU4KM7:TR?=	NWf5dotJW0GQR1XS
WM-115	NX\HRYROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoftTWM2OD1yLkCzO\|YzKM7:TR?=	MVnTRW5ITVJ?
DSH1	M3TZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjyTWM2OD1yLkCzPFA4KM7:TR?=	NVW4Xoo3W0GQR1XS
Becker	NUHjZ25yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXyVJlPUUN3ME2wMlA{QDh3IN88US=>	MWTTRW5ITVJ?
SW962	M3zZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXtTWM2OD1yLkCzPVQ2KM7:TR?=	Mn\VV2FPT0WU
TYK-nu	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\LToFKSzVyPUCuNFM6QDVizszN	M3vBfXNCVkeHUh?=
HO-1-N-1	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPIXGxrUUN3ME2wMlA1ODJzIN88US=>	NWPTPG1DW0GQR1XS
T98G	NHThSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnHTWM2OD1yLkC0NVA{KM7:TR?=	MmDzV2FPT0WU
ACN	M1HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe1VHl[UUN3ME2wMlA1OTZ{IN88US=>	NV7aOpM6W0GQR1XS
SW780	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLYTWM2OD1yLkC0NlA{KM7:TR?=	NF3YdpZUSU6JRWK=
Detroit562	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HLbmlEPTB;MD6wOFI{QSEQvF2=	NInnVZhUSU6JRWK=
BB49-HNC	NVL4fWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMESyOFMh\|ryP	MkXoV2FPT0WU
HN	M2PpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMESyO\|Ih\|ryP	NVv5SJJTW0GQR1XS
H9	NVK3OnBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r5XWlEPTB;MD6wOFM4OSEQvF2=	NYTGW4ZzW0GQR1XS
VA-ES-BJ	NFzGT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4C2T2lEPTB;MD6wOFQ1PyEQvF2=	M4LkV3NCVkeHUh?=
MEL-JUSO	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjrTWM2OD1yLkC0OFc2KM7:TR?=	NITDdGNUSU6JRWK=
BT-474	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLVTWM2OD1yLkC0OUDPxE1?	NI\FXmVUSU6JRWK=
CaR-1	NX7hUI95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHOTm1KSzVyPUCuNFQ2PDlizszN	M16zOnNCVkeHUh?=
PSN1	M4TX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj5dlZKSzVyPUCuNFQ3ODNizszN	MYTTRW5ITVJ?
KYSE-510	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrKcZFFUUN3ME2wMlA1PjR7IN88US=>	NUe4VmRoW0GQR1XS
KP-4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDlTWM2OD1yLkC0O\|U{KM7:TR?=	MWTTRW5ITVJ?
KYSE-410	NXT1U\|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7UTWM2OD1yLkC0O\|czKM7:TR?=	MlvLV2FPT0WU
G-402	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHEb21OUUN3ME2wMlA1Pzh7IN88US=>	MnjkV2FPT0WU
DOK	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXO1coZvUUN3ME2wMlA1QTB{IN88US=>	NXrRPYJ5W0GQR1XS
COR-L88	M1W0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm0d2ZKSzVyPUCuNFQ6OTJizszN	NU\GRXVwW0GQR1XS
SKG-IIIa	NF7xOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMES5PFYh\|ryP	NEjsVolUSU6JRWK=
AN3-CA	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XaUWlEPTB;MD6wOUDPxE1?	M2TBcHNCVkeHUh?=
SW48	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnSZnF3UUN3ME2wMlA2ODN7IN88US=>	NUXXOFhjW0GQR1XS
YKG-1	M{fzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLaXHZKSzVyPUCuNFUxPzFizszN	MnvrV2FPT0WU
KYSE-150	M2TFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIToR\|ZKSzVyPUCuNFUzOzVizszN	NG\Oe2ZUSU6JRWK=
HuO-3N1	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPwcHNFUUN3ME2wMlA2OjN5IN88US=>	Mo\HV2FPT0WU
LB1047-RCC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPGe4RKSzVyPUCuNFUzQTZizszN	M2DzO3NCVkeHUh?=
NCI-H2030	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjl[GtKSzVyPUCuNFU1OTRizszN	NV22U4EzW0GQR1XS
YH-13	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vUcmlEPTB;MD6wOVczOiEQvF2=	MXfTRW5ITVJ?
5637	NX;US4huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;zW5dZUUN3ME2wMlA2PzRizszN	M2PtTXNCVkeHUh?=
LOXIMVI	NHjxdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEW4O\|Ih\|ryP	NEe2[WdUSU6JRWK=
GT3TKB	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPZWYtKSzVyPUCuNFU6PDJizszN	Mm\rV2FPT0WU
TCCSUP	NV3Mb3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjQfFVKSzVyPUCuNFU6PjRizszN	M{P6ZnNCVkeHUh?=
EPLC-272H	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrjSJRUUUN3ME2wMlA3OjB3IN88US=>	NE\qe2ZUSU6JRWK=
LU-99A	MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvpVGl6UUN3ME2wMlA3OjN5IN88US=>	NVTIPYliW0GQR1XS
NCI-H1755	NFHidXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLTTWM2OD1yLkC2N\|QyKM7:TR?=	M37u[3NCVkeHUh?=
KM12	M3v2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrY[HlqUUN3ME2wMlA3OzR6IN88US=>	M{XDcXNCVkeHUh?=
SF295	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnKPGFtUUN3ME2wMlA3PDV{IN88US=>	MlrLV2FPT0WU
MZ2-MEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjNTWM2OD1yLkC2OVU{KM7:TR?=	Mn\RV2FPT0WU
HEC-1	M{SyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzEXmw3UUN3ME2wMlA3PTh6IN88US=>	MWDTRW5ITVJ?
SW684	M1jhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC1TWM2OD1yLkC2OVkyKM7:TR?=	NXjmfZNTW0GQR1XS
SF539	NFLPbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fRR2lEPTB;MD6wOlY5OSEQvF2=	M13zSXNCVkeHUh?=
GMS-10	NVXBfFE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDaTWM2OD1yLkC2Olk6KM7:TR?=	M{nu[nNCVkeHUh?=
MV-4-11	NX7BN5dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vzOmlEPTB;MD6wOlgxOyEQvF2=	NWfRVW9zW0GQR1XS
HT-29	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zkcWlEPTB;MD6wOlkyQSEQvF2=	NYe3NnZUW0GQR1XS
23132-87	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPhfGxiUUN3ME2wMlA3QTVizszN	MknZV2FPT0WU
SW620	M{Doe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfsNphKSzVyPUCuNFcxOjZizszN	M3jYdXNCVkeHUh?=
HCC1806	NXi2fYl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7Bc4lKSzVyPUCuNFcyOzFizszN	NIqz[\|JUSU6JRWK=
Hs-578-T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETzdVZKSzVyPUCuNFczODhizszN	M{ntOXNCVkeHUh?=
A2058	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3XU3lKSzVyPUCuNFczOjhizszN	M3vEWHNCVkeHUh?=
MEL-HO	NGrmVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLpTWM2OD1yLkC3NlU2KM7:TR?=	NX7ySZVUW0GQR1XS
HCC2998	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzwPWhKSzVyPUCuNFc{PDdizszN	M4XCUXNCVkeHUh?=
HuO9	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrrVYlKSzVyPUCuNFc2QDlizszN	NEXRc2xUSU6JRWK=
CAL-39	NI\vPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\SXFhKSzVyPUCuNFc4PjZizszN	NILUdFRUSU6JRWK=
M14	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4my[mlEPTB;MD6wO\|kyOyEQvF2=	M1S5OHNCVkeHUh?=
BFTC-909	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\UV2lEPTB;MD6wO\|k3QSEQvF2=	MUnTRW5ITVJ?
TE-11	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXm4e5lCUUN3ME2wMlA4QTl4IN88US=>	NHfUbVlUSU6JRWK=
TGBC1TKB	NH\FPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXew[\|JZUUN3ME2wMlA5ODR\|IN88US=>	MXvTRW5ITVJ?
L-363	NInS[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\4XllKSzVyPUCuNFgzODZizszN	MVXTRW5ITVJ?
A431	NETIToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfVTWM2OD1yLkC4NlEh\|ryP	MVfTRW5ITVJ?
MKN45	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEiyNVkh\|ryP	NETDPWdUSU6JRWK=
HT-1080	NYm0dlBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMEi0N\|kh\|ryP	NWPjZWpnW0GQR1XS
OVCAR-8	M2LDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\UfWlEPTB;MD6wPFYzOiEQvF2=	NGnqVphUSU6JRWK=
LCLC-97TM1	NVe5cpJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnvcHpGUUN3ME2wMlA5PzJ6IN88US=>	NHrr[VlUSU6JRWK=
M059J	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWyTWM2OD1yLkC5NFI4KM7:TR?=	NYjKcJJrW0GQR1XS
SK-MEL-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfjTWM2OD1yLkC5NFYh\|ryP	M2O3bnNCVkeHUh?=
TE-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH4XVdKSzVyPUCuNFkzODRizszN	MWjTRW5ITVJ?
KYSE-180	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz6XIVDUUN3ME2wMlA6OjZ{IN88US=>	NFzhS2RUSU6JRWK=
D-247MG	NYDTdZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LvUWlEPTB;MD6wPVQ2PSEQvF2=	NYTReG15W0GQR1XS
8-MG-BA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMEm0O\|Ih\|ryP	NUDLSXExW0GQR1XS
NCI-H1792	NEmweVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfiTWM2OD1yLkC5OlE5KM7:TR?=	NIC4OXpUSU6JRWK=
MCF7	Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\6PGlEPTB;MD6wPVY4PyEQvF2=	MWnTRW5ITVJ?
NCI-H2122	NYW4PYZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1eyOGlEPTB;MD6wPVc1PSEQvF2=	NVTzb2V4W0GQR1XS
EFO-27	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\rSGlEPTB;MD6wPVk6PyEQvF2=	NVHwT5JIW0GQR1XS
LB2241-RCC	NGPjdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMUCwOVQh\|ryP	MonQV2FPT0WU
SN12C	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnyOYNtUUN3ME2wMlExOTB5IN88US=>	M{juVXNCVkeHUh?=
A498	M{XTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzEeFBKSzVyPUCuNVAyQCEQvF2=	NITQS45USU6JRWK=
PANC-03-27	NFLyW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrqcnF3UUN3ME2wMlExOjh4IN88US=>	NUWydmI1W0GQR1XS
NCI-H1581	NHPxNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\Xb2lEPTB;MD6xNFI6KM7:TR?=	NI\Me3RUSU6JRWK=
U-87-MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PxOmlEPTB;MD6xNFMxPyEQvF2=	Ml3KV2FPT0WU
G-401	NG\KbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMUCzOVMh\|ryP	M{m3VXNCVkeHUh?=
SiHa	NHO4cFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPGTWM2OD1yLkGwOFg3KM7:TR?=	MoHjV2FPT0WU
U251	NXjDR29XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMUC1NlUh\|ryP	MYLTRW5ITVJ?
MMAC-SF	NY\QOll4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLVTWM2OD1yLkGwOVMyKM7:TR?=	M4jQNXNCVkeHUh?=
BB65-RCC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFqwWWJKSzVyPUCuNVA2PTRizszN	NV22Xms1W0GQR1XS
NKM-1	NET5NZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3G4W2lEPTB;MD6xNFY3PiEQvF2=	NVTOfXlWW0GQR1XS
HD-MY-Z	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDrO4NKSzVyPUCuNVA5PzNizszN	M3GwfnNCVkeHUh?=
TGBC11TKB	NYXhb2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DFTWlEPTB;MD6xNFkxOyEQvF2=	MVrTRW5ITVJ?
COLO-679	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYewN4JPUUN3ME2wMlEyOjFzIN88US=>	NWPDTHlvW0GQR1XS
TE-8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrlSZJUUUN3ME2wMlEyOjZ2IN88US=>	MUPTRW5ITVJ?
SK-MEL-28	M2HVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWGzcVdOUUN3ME2wMlEyOzJzIN88US=>	MXXTRW5ITVJ?
SH-4	NXHkUFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nHXmlEPTB;MD6xNVM2PiEQvF2=	MmW2V2FPT0WU
KALS-1	NXzWW29HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYToVFEzUUN3ME2wMlEyOzl\|IN88US=>	Ml7JV2FPT0WU
RKO	NYTpTGxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M32wXmlEPTB;MD6xNVc3PCEQvF2=	NEXCT2ZUSU6JRWK=
OMC-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMUG3PVch\|ryP	Mnr3V2FPT0WU
BT-549	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHHSG5KSzVyPUCuNVE4QTlizszN	Mn;2V2FPT0WU
NCI-H28	NUm2SnpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjpTWM2OD1yLkGxPFE4KM7:TR?=	NGCzVJhUSU6JRWK=
RXF393	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XXbGlEPTB;MD6xNVk5OiEQvF2=	Mni3V2FPT0WU
COLO-829	NVTu[\|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXGWW9KSzVyPUCuNVIxODVizszN	NUPrVHpDW0GQR1XS
HMV-II	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMUKwNkDPxE1?	M4e0S3NCVkeHUh?=
SW1990	NY\2XVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;5dXNKSzVyPUCuNVIyPTdizszN	NGC5cYdUSU6JRWK=
NCI-H1437	NWTPZ2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMUKxOVch\|ryP	NV3t[lBuW0GQR1XS
SNB75	M3HTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMUKxOlkh\|ryP	MWPTRW5ITVJ?
EW-3	NXXScFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[zNIFKSzVyPUCuNVI3PjFizszN	MmrzV2FPT0WU
SAS	M1zsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mln1TWM2OD1yLkGyOlkh\|ryP	MmmwV2FPT0WU
NCI-H1666	NVyzOXdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrSUWFKSzVyPUCuNVI4PzRizszN	NFjOVm1USU6JRWK=
A375	M1faN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTMWGQzUUN3ME2wMlEzPzd6IN88US=>	MXXTRW5ITVJ?
CAMA-1	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fTXmlEPTB;MD6xNlkzPCEQvF2=	NV3oXohPW0GQR1XS
HuP-T4	NHHvepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYftfpdmUUN3ME2wMlEzQTR\|IN88US=>	MUDTRW5ITVJ?
NCI-H292	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jYTGlEPTB;MD6xN\|EyKM7:TR?=	MX\TRW5ITVJ?
PC-14	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHFOo5KSzVyPUCuNVMzOTFizszN	MXrTRW5ITVJ?
BPH-1	NIji[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPjVJpWUUN3ME2wMlE{PDFizszN	NUHhRos3W0GQR1XS
GAK	M4DYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMUO1Olch\|ryP	M2XEWnNCVkeHUh?=
VMRC-RCZ	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTyTWM2OD1yLkGzO\|YzKM7:TR?=	NHntVmpUSU6JRWK=
SK-MEL-24	MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULSN4d4UUN3ME2wMlE{QDdizszN	M{PPRnNCVkeHUh?=
LB831-BLC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnMfYVKSzVyPUCuNVM5QDNizszN	M2izT3NCVkeHUh?=
NCI-H2452	NWez[\|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2naO2lEPTB;MD6xN\|k2PiEQvF2=	M3:wbnNCVkeHUh?=
RT-112	NVjZNoVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLJ[WpjUUN3ME2wMlE1ODN3IN88US=>	MlPJV2FPT0WU
GP5d	NIfnT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMUSxNFQh\|ryP	NEnrT\|hUSU6JRWK=
LC-2-ad	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLxdWhQUUN3ME2wMlE1OTJzIN88US=>	NXLsWnJ7W0GQR1XS
MPP-89	NFWzbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrFTWM2OD1yLkG0NVI2KM7:TR?=	NGC2RYxUSU6JRWK=
NUGC-3	NXu2V5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTtbmxmUUN3ME2wMlE1PDd6IN88US=>	MVzTRW5ITVJ?
GI-1	M{j6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPpTmZoUUN3ME2wMlE1PTV6IN88US=>	MYDTRW5ITVJ?
HCC1419	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjQSGFjUUN3ME2wMlE1PTd4IN88US=>	MUPTRW5ITVJ?
SW1573	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGWxSmFKSzVyPUCuNVQ4PThizszN	MlfNV2FPT0WU
NCI-H2347	NHm3[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLmTWM2OD1yLkG0PFM6KM7:TR?=	M4HsWXNCVkeHUh?=
Mewo	NXzVWlYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;YTWM2OD1yLkG0PFg6KM7:TR?=	MUPTRW5ITVJ?
639-V	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkj3TWM2OD1yLkG1NFE{KM7:TR?=	MV7TRW5ITVJ?
AsPC-1	NHK1SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlP5TWM2OD1yLkG1NlI2KM7:TR?=	M2n6RXNCVkeHUh?=
NCI-H1648	NUfEVmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrPbmtKUUN3ME2wMlE2OjN{IN88US=>	MmrUV2FPT0WU
786-0	NHzqbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInG[HVKSzVyPUCuNVU{QDFizszN	Mk\GV2FPT0WU
ETK-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMUW5JO69VQ>?	NH\GN4NUSU6JRWK=
BxPC-3	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\yOY9KSzVyPUCuNVU6PjZizszN	M3raO3NCVkeHUh?=
CAL-62	NELtNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDhdpN5UUN3ME2wMlE3OTZ7IN88US=>	M2jwZnNCVkeHUh?=
HCC1937	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInVR4JKSzVyPUCuNVYzPzVizszN	MmnCV2FPT0WU
NCI-H1299	NXPBV5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LJR2lEPTB;MD6xOlI5PSEQvF2=	NV\GTFRyW0GQR1XS
SW1088	M3jaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMU[0NVMh\|ryP	NXPmOYhSW0GQR1XS
FTC-133	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnxSJNKSzVyPUCuNVY2PCEQvF2=	MmrYV2FPT0WU
OC-314	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjmTWM2OD1yLkG2Olkh\|ryP	MmjLV2FPT0WU
SCC-9	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIX4d2FKSzVyPUCuNVY4OTZizszN	NGXXXnZUSU6JRWK=
HT-1376	NHHGdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvGfWpZUUN3ME2wMlE3QTN4IN88US=>	M{PEN3NCVkeHUh?=
U-2-OS	NXjjXIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMUexO\|Mh\|ryP	NVP3cJQ1W0GQR1XS
COLO-824	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[0TWM2OD1yLkG3Nlk1KM7:TR?=	MVXTRW5ITVJ?
BB30-HNC	M4rJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\TRYZKSzVyPUCuNVc{OyEQvF2=	MXrTRW5ITVJ?
NCI-H2087	M4[2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TJZWlEPTB;MD6xO\|M3QCEQvF2=	NVT4W5J5W0GQR1XS
NCI-H2170	NHfheFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnLUZZKSzVyPUCuNVc2OzZizszN	M{e1SHNCVkeHUh?=
SK-OV-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\5TWM2OD1yLkG3OVcyKM7:TR?=	MV3TRW5ITVJ?
MZ7-mel	NIDMPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rJfmlEPTB;MD6xO\|Y1QSEQvF2=	NX36[YZxW0GQR1XS
NCI-H650	NIXLcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrMVGZVUUN3ME2wMlE4Pjh{IN88US=>	MWTTRW5ITVJ?
KOSC-2	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMUe3N\|Qh\|ryP	MmPtV2FPT0WU
SCC-4	NEP4S\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPwSYdKSzVyPUCuNVc4PzdizszN	M1TIOnNCVkeHUh?=
MDA-MB-157	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\VTWM2OD1yLkG4NFgzKM7:TR?=	MXzTRW5ITVJ?
KYSE-520	NVSxUpU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXCeGdKSzVyPUCuNVgzKM7:TR?=	NUDPTVVbW0GQR1XS
LK-2	M4DufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DKdGlEPTB;MD6xPFMxOyEQvF2=	NFexNJlUSU6JRWK=
KNS-81-FD	M3LIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjYWJdsUUN3ME2wMlE5Ozl2IN88US=>	NF34NFVUSU6JRWK=
IGROV-1	NHjFfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPSTWM2OD1yLkG4OFQ{KM7:TR?=	NIjRcGpUSU6JRWK=
DEL	M2Swcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTLU5RKSzVyPUCuNVg1PSEQvF2=	M{W2WnNCVkeHUh?=
NCI-H1395	NHr0UmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrmOGl[UUN3ME2wMlE5Pjh{IN88US=>	NWDpcIxGW0GQR1XS
JEG-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXEV2w{UUN3ME2wMlE5PzB3IN88US=>	NWPqdpNHW0GQR1XS
BCPAP	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMUi4O\|Ih\|ryP	MknjV2FPT0WU
CAL-27	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;vTlZHUUN3ME2wMlE6ODJ{IN88US=>	MXLTRW5ITVJ?
RD	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMUmxNVMh\|ryP	M{D6cHNCVkeHUh?=
RVH-421	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMUmxNVYh\|ryP	MmrqV2FPT0WU
Capan-2	M3TvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mki1TWM2OD1yLkG5NlU3KM7:TR?=	M2GzXnNCVkeHUh?=
COLO-680N	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf3UFlKSzVyPUCuNVk{PjRizszN	NV\a[5RwW0GQR1XS
NCI-H1650	M1S4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljmTWM2OD1yLkKwNFU4KM7:TR?=	MXzTRW5ITVJ?
SBC-5	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFe4UHFKSzVyPUCuNlAyOThizszN	NH7SVmdUSU6JRWK=
U031	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPaTWM2OD1yLkKwOVQ4KM7:TR?=	NVfoWlNMW0GQR1XS
S-117	M2\0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMkC1OlQh\|ryP	M2D2ZnNCVkeHUh?=
DoTc2-4510	NFTYUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXwO4hKSzVyPUCuNlA4PjlizszN	M1XvUHNCVkeHUh?=
AM-38	M{n5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXU[WFXUUN3ME2wMlIxQDR6IN88US=>	MVHTRW5ITVJ?
A172	NVfXS3U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXxTnRKSzVyPUCuNlExOjJizszN	MXzTRW5ITVJ?
HPAF-II	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrtOpdzUUN3ME2wMlIyOjZ2IN88US=>	M4\5XXNCVkeHUh?=
769-P	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTrZ\|hKSzVyPUCuNlEzQCEQvF2=	NYHkSXVVW0GQR1XS
MFE-280	NFrF[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPTUG1KSzVyPUCuNlEzQThizszN	NXj4eoZ{W0GQR1XS
TE-9	NULsSohET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fib2lEPTB;MD6yNVc5PiEQvF2=	Mn;JV2FPT0WU
C2BBe1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33HPWlEPTB;MD6yNlE6KM7:TR?=	NUO2ZlBwW0GQR1XS
EoL-1-cell	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvXW5ZoUUN3ME2wMlIzOjB\|IN88US=>	MW\TRW5ITVJ?
G-361	M2Pncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XNZ2lEPTB;MD6yNlY5OiEQvF2=	NIDYb3BUSU6JRWK=
KYSE-270	NHPxVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq5UFdKSzVyPUCuNlMxQDRizszN	Mo\wV2FPT0WU
TK10	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMkOxNVch\|ryP	MlH6V2FPT0WU
ML-2	M3G0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDySVNKSzVyPUCuNlMyOTlizszN	NV\3PXBqW0GQR1XS
MHH-ES-1	NF;1Z5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofmTWM2OD1yLkKzOlgyKM7:TR?=	NEfkN3FUSU6JRWK=
BHY	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PMbGlEPTB;MD6yN\|Y6OSEQvF2=	MWrTRW5ITVJ?
LS-513	NUnkUGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDlTWM2OD1yLkKzPVYyKM7:TR?=	Mmq4V2FPT0WU
COLO-678	NFPTNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoS0TWM2OD1yLkK0NFQ1KM7:TR?=	NHXoOVNUSU6JRWK=
NCI-H747	NXzBNW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOyTWM2OD1yLkK0NVY6KM7:TR?=	MkK4V2FPT0WU
K5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nMfmlEPTB;MD6yOFM5KM7:TR?=	MWfTRW5ITVJ?
OS-RC-2	MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVSwNWtpUUN3ME2wMlI1PTB7IN88US=>	Ml30V2FPT0WU
KINGS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW3TWM2OD1yLkK0OVI6KM7:TR?=	M{XPfnNCVkeHUh?=
SCC-25	NXixSGZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\WU4VKSzVyPUCuNlQ2PjNizszN	MVLTRW5ITVJ?
CAPAN-1	NXjOU5hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPjdW1SUUN3ME2wMlI1Pzh\|IN88US=>	M37we3NCVkeHUh?=
ESS-1	M4nTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnmRmNKSzVyPUCuNlQ5ODVizszN	MUnTRW5ITVJ?
TE-6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfkO4VFUUN3ME2wMlI2PzVizszN	MV3TRW5ITVJ?
LB2518-MEL	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf2TVF3UUN3ME2wMlI2Pzd5IN88US=>	M4LxXXNCVkeHUh?=
COLO-800	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvxfZBOUUN3ME2wMlI2QDF{IN88US=>	Mn60V2FPT0WU
LU-134-A	NFzrSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMk[xN\|Yh\|ryP	M1rNNnNCVkeHUh?=
NCI-H1155	NFqzSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkG0TWM2OD1yLkK2NVYzKM7:TR?=	NIPjb\|NUSU6JRWK=
MFM-223	NVixSnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPnTWM2OD1yLkK2N\|Y{KM7:TR?=	NWnkNXBLW0GQR1XS
HTC-C3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWmwSYVmUUN3ME2wMlI3PTB4IN88US=>	Mo[zV2FPT0WU
HCT-116	NXnaUVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnlOnJDUUN3ME2wMlI3PTl7IN88US=>	NX;6d\|dJW0GQR1XS
Ca-Ski	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMk[2O\|gh\|ryP	NE\u[GRUSU6JRWK=
SBC-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DRbGlEPTB;MD6yOlc1OiEQvF2=	MkHYV2FPT0WU
NB69	NIPQTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4mxTGlEPTB;MD6yO\|A5PyEQvF2=	M{PxeHNCVkeHUh?=
J82	NIHuXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\OTWM2OD1yLkK3NlY2KM7:TR?=	M4fmXXNCVkeHUh?=
U-118-MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vob2lEPTB;MD6yO\|U4QSEQvF2=	M{HYT3NCVkeHUh?=
NCI-H1355	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m5ZmlEPTB;MD6yPFA4PCEQvF2=	MYTTRW5ITVJ?
NCI-H1048	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzodIxKSzVyPUCuNlg6PTZizszN	MX;TRW5ITVJ?
SW954	M1HOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MluxTWM2OD1yLkK5NlI4KM7:TR?=	NEj6Rm9USU6JRWK=
NMC-G1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX4c4hKUUN3ME2wMlI6Ojd5IN88US=>	MnHRV2FPT0WU
SW1710	NIm5U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf4TWM2OD1yLkK5OFk1KM7:TR?=	MVLTRW5ITVJ?
KY821	NGXXfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HrUmlEPTB;MD6yPVg4OiEQvF2=	M3K2fHNCVkeHUh?=
HCC38	M17ZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrsSpR4UUN3ME2wMlMxODd6IN88US=>	M36yeHNCVkeHUh?=
NCI-SNU-5	NXrH[nNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH33Z2JKSzVyPUCuN\|A2PCEQvF2=	M{f0W3NCVkeHUh?=
ES8	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP2No9CUUN3ME2wMlMxPzh2IN88US=>	M{TOWHNCVkeHUh?=
COLO-792	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\pPFBGUUN3ME2wMlMyOjVzIN88US=>	NIfvNVBUSU6JRWK=
BFTC-905	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELV[3hKSzVyPUCuN\|E2OjFizszN	NIL1ZlRUSU6JRWK=
ChaGo-K-1	NV;GOXMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXi[415UUN3ME2wMlMyPzF3IN88US=>	M3fONnNCVkeHUh?=
Daoy	NGfaUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zwW2lEPTB;MD6zNVczOyEQvF2=	NHzkXWpUSU6JRWK=
SJSA-1	MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33pXWlEPTB;MD6zNVg1PyEQvF2=	NG\KcFdUSU6JRWK=
KNS-62	MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi3TWM2OD1yLkOyNFg5KM7:TR?=	NXXrUoN2W0GQR1XS
CAKI-1	NITMUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwM{KxNVEh\|ryP	NI\YZpdUSU6JRWK=
UACC-62	NX\iVIdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf0N3FKSzVyPUCuN\|IzOjdizszN	NF7MPZVUSU6JRWK=
HuCCT1	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1yxSWlEPTB;MD6zNlI5OyEQvF2=	MUTTRW5ITVJ?
CTB-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkD1TWM2OD1yLkOyO\|U{KM7:TR?=	M{fWWnNCVkeHUh?=
NTERA-S-cl-D1	NV\YfXRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwM{K4N\|Yh\|ryP	NUDyOXBRW0GQR1XS
T-24	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4q2eWlEPTB;MD6zN\|E2QSEQvF2=	NWjOWmhRW0GQR1XS
KYSE-70	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vE[mlEPTB;MD6zN\|I5OyEQvF2=	MkjJV2FPT0WU
SW626	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwM{O1N\|Ih\|ryP	MonBV2FPT0WU
LB996-RCC	NIXJUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPJTWM2OD1yLkOzOlE6KM7:TR?=	MkK4V2FPT0WU
DMS-273	NFrPenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDnTWM2OD1yLkOzPVE3KM7:TR?=	MUnTRW5ITVJ?
SW1783	NYHER4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXUfmJKSzVyPUCuN\|M6QTdizszN	NY\B[XRDW0GQR1XS
KU812	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnLTXJKSzVyPUCuN\|QxOzhizszN	NX6zeHNtW0GQR1XS
HSC-2	NXzTVZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XHd2lEPTB;MD6zOFA2OyEQvF2=	NIDjNlZUSU6JRWK=
A3-KAW	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1G1bmlEPTB;MD6zOFE3OiEQvF2=	MnzuV2FPT0WU
COLO-684	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[wTWM2OD1yLkO0OVAyKM7:TR?=	NIrUWo1USU6JRWK=
NCI-H2405	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTPXFZpUUN3ME2wMlM1PjNzIN88US=>	MWTTRW5ITVJ?
NCI-H2228	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nxdmlEPTB;MD6zOVM2PyEQvF2=	MnPyV2FPT0WU
NB13	NFP2ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTKTWM2OD1yLkO2PFI6KM7:TR?=	MXfTRW5ITVJ?
no-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwM{[5OUDPxE1?	M{W1O3NCVkeHUh?=
DK-MG	NELEPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwM{exPFgh\|ryP	NI\SNm5USU6JRWK=
NBsusSR	M1;ISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i0NGlEPTB;MD6zO\|I5PSEQvF2=	M1fHXXNCVkeHUh?=
KP-N-YS	NVXKUmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFG5bJRKSzVyPUCuN\|c1PjNizszN	MlS2V2FPT0WU
CFPAC-1	NIm5cHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwM{e1NVgh\|ryP	NY[3eZpEW0GQR1XS
KARPAS-45	NXTFc2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr0Z4hqUUN3ME2wMlM4QDZ{IN88US=>	NHnFdmZUSU6JRWK=
NCI-H1793	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7vR\|JKSzVyPUCuN\|g2OSEQvF2=	MX7TRW5ITVJ?
HCE-T	NWnQ[nVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHaN5RKSzVyPUCuN\|g3ODNizszN	Mle3V2FPT0WU
NCI-H520	M1nUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwM{i3NFMh\|ryP	MXTTRW5ITVJ?
HCC2157	M2fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHyTWM2OD1yLkO4O\|gyKM7:TR?=	MWjTRW5ITVJ?
EW-18	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwM{i5OFEh\|ryP	M3rq[HNCVkeHUh?=
RO82-W-1	NYjNcJRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PEV2lEPTB;MD6zPVY6QSEQvF2=	NUXpeI5XW0GQR1XS
HuP-T3	NGLT[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwNECxOFMh\|ryP	M2TD[XNCVkeHUh?=
PANC-10-05	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HFSGlEPTB;MD60NVE4KM7:TR?=	Mof6V2FPT0WU
NCI-H1703	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnJTWM2OD1yLkSxOFQ3KM7:TR?=	NVPJcHp3W0GQR1XS
TE-10	M33mTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjpRVVKSzVyPUCuOFE1PDdizszN	NIPVNJJUSU6JRWK=
HOS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFL4Um1KSzVyPUCuOFE3QDJizszN	NXHF[GxKW0GQR1XS
LN-405	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf5NJFKSzVyPUCuOFE3QDdizszN	Ml65V2FPT0WU
A427	M1nWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2K1[WlEPTB;MD60NVk5OSEQvF2=	MoDPV2FPT0WU
CAL-12T	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\3TWM2OD1yLkSyO\|gh\|ryP	M1\Z[XNCVkeHUh?=
SW756	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwNESxPFMh\|ryP	MYfTRW5ITVJ?
YAPC	M1S3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNEWwPEDPxE1?	MYTTRW5ITVJ?
GOTO	NV\vTFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PNPWlEPTB;MD60OVE3KM7:TR?=	NXfKUZcyW0GQR1XS
C3A	M1TISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHiXXBKSzVyPUCuOFU1OzdizszN	MlfHV2FPT0WU
UM-UC-3	M{fON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDyb2ZKSzVyPUCuOFU1PyEQvF2=	NHPxbZpUSU6JRWK=
NCI-H1573	NW[0OG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\1WmlEPTB;MD60OVU3QSEQvF2=	MVPTRW5ITVJ?
LS-411N	NE\zRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLCTWM2OD1yLkS2OVI4KM7:TR?=	NIPLTFFUSU6JRWK=
COR-L23	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfrTWM2OD1yLkS2O\|Y1KM7:TR?=	MYrTRW5ITVJ?
HCE-4	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT0TWM2OD1yLkS3OFQ3KM7:TR?=	MnfVV2FPT0WU
NCI-H2291	NWO3XnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwNEe4PVYh\|ryP	M4S4PHNCVkeHUh?=
A101D	NUnuT5N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkizTWM2OD1yLkS4NFU{KM7:TR?=	MUDTRW5ITVJ?
HT-3	NFXYTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwNEiyNVch\|ryP	MYTTRW5ITVJ?
HOP-62	M1vjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwNEm4OlUh\|ryP	NH3rWVRUSU6JRWK=
PC-3	M{jOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknZTWM2OD1yLkWxOVA4KM7:TR?=	NV;SZ2ZjW0GQR1XS
CTV-1	NH2xeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwNUK2Olkh\|ryP	MkjZV2FPT0WU
PANC-08-13	NGfaU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDJcpZyUUN3ME2wMlU{OTd5IN88US=>	M4X6NXNCVkeHUh?=
CAL-120	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvhRYhnUUN3ME2wMlU{Ozl7IN88US=>	MUDTRW5ITVJ?
UMC-11	M3jPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwNUWyN\|Qh\|ryP	MmDWV2FPT0WU
MSTO-211H	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTPeFRKSzVyPUCuOVU4PjJizszN	M1zxRXNCVkeHUh?=
NCI-H2126	NGHTcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDSco5KSzVyPUCuOVY5OTVizszN	M4CzXnNCVkeHUh?=
SNU-C2B	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrCdnJKSzVyPUCuOVc6PzdizszN	MVLTRW5ITVJ?
DBTRG-05MG	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwNUiwOVMh\|ryP	MUfTRW5ITVJ?
MKN1	M1zpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHTcHJKSzVyPUCuOVg4QDNizszN	NUW4XoVTW0GQR1XS
ES3	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm0TWM2OD1yLkW5NVI1KM7:TR?=	MnO5V2FPT0WU
OVCAR-3	NHu5WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIniWIhKSzVyPUCuOVk{PDFizszN	M4jZenNCVkeHUh?=
ACHN	NGrDT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrjfXRKSzVyPUCuOlA2PjlizszN	MXTTRW5ITVJ?
SW872	NY\QcVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS4VlVKSzVyPUCuOlA4PjNizszN	NEDWdYlUSU6JRWK=
CP66-MEL	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHVTWM2OD1yLk[wPVY6KM7:TR?=	Mm[1V2FPT0WU
NCI-H661	NYjvZ4llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlToTWM2OD1yLk[xNVA1KM7:TR?=	MYTTRW5ITVJ?
UACC-893	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\QUVZKSzVyPUCuOlM3QDFizszN	NFKzU3hUSU6JRWK=
JVM-3	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;BW4ZKSzVyPUCuOlM5ODRizszN	MnfCV2FPT0WU
SF268	NIPLVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF65SGFKSzVyPUCuOlQ{PDlizszN	NU\WZop6W0GQR1XS
OCI-AML2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTOTWM2OD1yLk[1N\|k4KM7:TR?=	MXPTRW5ITVJ?
RPMI-8226	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTWSnlKSzVyPUCuOlY{OjNizszN	MXTTRW5ITVJ?
MKN28	M33QfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnITWM2OD1yLk[2OlI1KM7:TR?=	NGewTIRUSU6JRWK=
MDA-MB-453	NXfSb4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwNkexPEDPxE1?	M3j5VnNCVkeHUh?=
BV-173	NIfPVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj5TWM2OD1yLk[4Olc6KM7:TR?=	NVHHbFBVW0GQR1XS
NCI-H358	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwNki3NlYh\|ryP	NFm0e3dUSU6JRWK=
NCI-H1651	MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwNzFOwG0>	MVTTRW5ITVJ?
MDA-MB-415	NYSxb4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwN{C4Nlkh\|ryP	NHmxT2VUSU6JRWK=
8305C	NF74OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;xTWM2OD1yLkeyOFk5KM7:TR?=	NHjqemxUSU6JRWK=
EFM-19	NVvndXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwN{O2O\|Eh\|ryP	MUfTRW5ITVJ?
RERF-LC-MS	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37mZmlEPTB;MD63OFYyOyEQvF2=	MUfTRW5ITVJ?
A388	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEK3UINKSzVyPUCuO\|Y1PjdizszN	MV\TRW5ITVJ?
GI-ME-N	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi4[FlKSzVyPUCuO\|czOzVizszN	Mly0V2FPT0WU
IGR-1	NUfKTXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwN{mwOFMh\|ryP	MYfTRW5ITVJ?
LNCaP-Clone-FGC	M1HlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPGTWM2OD1yLkiwNFA1KM7:TR?=	NYrsV3NwW0GQR1XS
SK-MEL-3	NFrlNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1raN2lEPTB;MD64NVUxQCEQvF2=	NXP5dY9rW0GQR1XS
UACC-257	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[xbHpKSzVyPUCuPFIzOzFizszN	MXTTRW5ITVJ?
OE33	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETBbY1KSzVyPUCuPFUyODFizszN	NIPkW2RUSU6JRWK=
QIMR-WIL	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXsSVVGUUN3ME2wMlg2OTRzIN88US=>	NWXHcYhmW0GQR1XS
NCI-H2009	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PrU2lEPTB;MD64OVMyOSEQvF2=	MljkV2FPT0WU
NCI-H522	NGS2cJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXpeWRKSzVyPUCuPFc4QDNizszN	MmDpV2FPT0WU
Saos-2	M17INmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu0bHpKSzVyPUCuPFc5PzFizszN	Mn3TV2FPT0WU
NB17	NFzHcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrteIRKSzVyPUCuPFgxOjVizszN	MnLqV2FPT0WU
D-392MG	NXXRUHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fJRWlEPTB;MD64PVM2PiEQvF2=	MUDTRW5ITVJ?
SHP-77	NIn4UIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPvTWM2OD1yLkmwOFg2KM7:TR?=	NWm0TnI{W0GQR1XS
SK-MEL-30	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHJN4J1UUN3ME2wMlkyOTh3IN88US=>	NIHRNIpUSU6JRWK=
GCIY	NU\EVFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFWydmdKSzVyPUCuPVE5PDNizszN	M{WwSXNCVkeHUh?=
HCC70	NYPueGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PUTWlEPTB;MD65NlA2QSEQvF2=	NIjTV3ZUSU6JRWK=
LU-65	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjFWHNKSzVyPUCuPVI2QTFizszN	M1vTUXNCVkeHUh?=
NCI-H1563	NIPxSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwOUS4OlUh\|ryP	NIfyWVlUSU6JRWK=
KURAMOCHI	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:2[WlEPTB;MD65OVE6OiEQvF2=	NVKxfI9lW0GQR1XS
PA-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LsSmlEPTB;MD65OVQzPCEQvF2=	MYPTRW5ITVJ?
NOS-1	M{nHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jOUGlEPTB;MD65O\|Q5QSEQvF2=	NUTUTJVbW0GQR1XS
NCI-H69	NHT6bJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTGTWM2OD1yLkm3OlM1KM7:TR?=	NHjNNY1USU6JRWK=
KYSE-450	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDxTWM2OD1yLkm4OlI3KM7:TR?=	M{LwR3NCVkeHUh?=
8505C	NWC5U5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HKdGlEPTB;MD65PVk5OiEQvF2=	MknRV2FPT0WU
TGBC24TKB	NXXGXlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFH3T5NKSzVyPUGuNFAxQDRizszN	MWPTRW5ITVJ?
PFSK-1	NXvOR3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{ft[2lEPTB;MT6wNVQzQCEQvF2=	NF\JcGdUSU6JRWK=
EKVX	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorOTWM2OD1zLkCzNVIyKM7:TR?=	NELsZ2FUSU6JRWK=
RCM-1	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHKPY5KSzVyPUGuNFU2ODdizszN	MXTTRW5ITVJ?
SW900	NX7pUFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwMEe4N{DPxE1?	NWThU5FzW0GQR1XS
D-542MG	MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\lbmlEPTB;MT6wO\|g2PSEQvF2=	MlS4V2FPT0WU
SK-PN-DW	NI\KXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nzc2lEPTB;MT6xNFA2PiEQvF2=	NF;Ke45USU6JRWK=
NCI-H727	M3S5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfPNmZKSzVyPUGuNVAyPTRizszN	NYrTT3lxW0GQR1XS
SW837	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnVTWM2OD1zLkGwPVU1KM7:TR?=	MWHTRW5ITVJ?
BT-20	NUPibFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfRTWM2OD1zLkGxNlA1KM7:TR?=	NGPqeIlUSU6JRWK=
RH-18	NFjnUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzMVJBsUUN3ME2xMlE{OTB\|IN88US=>	NYLleJZsW0GQR1XS
TE-12	NWLpPHE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFwMUOzN\|Mh\|ryP	NHLjR5lUSU6JRWK=
NB10	NFnnbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTkTWM2OD1zLkGzN\|Q1KM7:TR?=	MXjTRW5ITVJ?
AU565	NGDGdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzjTWM2OD1zLkG1PVc{KM7:TR?=	NFTyO2FUSU6JRWK=
OAW-42	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljGTWM2OD1zLkG4N\|A3KM7:TR?=	MVfTRW5ITVJ?
DJM-1	NFvpWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ThU2lEPTB;MT6xPVg5OSEQvF2=	NYe0ZVl{W0GQR1XS
HH	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFwMkO4N\|Eh\|ryP	NFyyZoNUSU6JRWK=
LAMA-84	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrQflNQUUN3ME2xMlI4Ozl2IN88US=>	M2\rTnNCVkeHUh?=
KNS-42	M{faVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T2fGlEPTB;MT6zNFI6PiEQvF2=	NFTFSotUSU6JRWK=
NCI-H2052	NVWx[JU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PLTmlEPTB;MT6zNFUxPyEQvF2=	MoPTV2FPT0WU
MLMA	NWnycoJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXRXHFKSzVyPUGuN\|I1ODdizszN	M1fxWXNCVkeHUh?=
NB12	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFwM{W2N\|Yh\|ryP	NVT6OmkxW0GQR1XS
NCI-H1838	M3i5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTUbW5KSzVyPUGuN\|Y{ODZizszN	NFfzPZBUSU6JRWK=
NCI-H526	NGLo[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrHTWM2OD1zLkO3PFU{KM7:TR?=	MWnTRW5ITVJ?
LS-123	M3vxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXpTWM2OD1zLkO5NFk1KM7:TR?=	Mk\KV2FPT0WU
HDLM-2	NYDqPFhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjDTWM2OD1zLkO5NlcyKM7:TR?=	MVHTRW5ITVJ?
MC-IXC	NGnGNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvpVoRKSzVyPUGuOFI{PzFizszN	NE\jb4dUSU6JRWK=
HCT-15	M3vJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\UTWM2OD1zLkSzNFY5KM7:TR?=	NV76OHVIW0GQR1XS
NCI-H596	M4LSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DlXWlEPTB;MT60OVA3OSEQvF2=	NYLpXpNRW0GQR1XS
ZR-75-30	NHLkNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj1TWM2OD1zLkS3NFgzKM7:TR?=	NVvH[ohKW0GQR1XS
A704	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHmTWM2OD1zLk[2OVY{KM7:TR?=	M4TXNXNCVkeHUh?=
OVCAR-4	NWD1SFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\seGlEPTB;MT62PVYxPyEQvF2=	MnLCV2FPT0WU
SW1417	MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HicGlEPTB;MT63Nlg1QSEQvF2=	MVrTRW5ITVJ?
CAS-1	NEi1WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXjTWM2OD1zLkezPVM3KM7:TR?=	MmLiV2FPT0WU
IST-SL1	M4WxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLhTWM2OD1zLke5O\|U6KM7:TR?=	MVXTRW5ITVJ?
A253	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwOEKyN\|kh\|ryP	MoXVV2FPT0WU
EW-16	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzHTWM2OD1zLkiyPFc2KM7:TR?=	MVXTRW5ITVJ?
SK-NEP-1	NV\0VVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TRWmlEPTB;MT64Olk5QCEQvF2=	MmHCV2FPT0WU
NCI-H226	M3TGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7T[pRKSzVyPUGuPFk{PTlizszN	MVrTRW5ITVJ?
HOP-92	NIn5XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGX0O\|ZKSzVyPUGuPVYxQTlizszN	M{nL[3NCVkeHUh?=
NCI-H441	M4jhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG3TmNKSzVyPUKuNFI{OzdizszN	MmH4V2FPT0WU
LU-139	M{HGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37CXGlEPTB;Mj6wN\|EyPCEQvF2=	NXLVcldMW0GQR1XS
SJRH30	M{\BcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2j6RmlEPTB;Mj6wOFI2OyEQvF2=	NF3nb5pUSU6JRWK=
MG-63	NH;uZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTJwMUSxNVEh\|ryP	MnH4V2FPT0WU
NH-12	M1LDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jN[WlEPTB;Mj6xOVAxPiEQvF2=	MlW1V2FPT0WU
NB7	NHPBfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFe2fGRKSzVyPUKuNVk3PzNizszN	M3XrWHNCVkeHUh?=
LB771-HNC	M3fMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;DSGhKSzVyPUKuNlA2QTVizszN	Ml2zV2FPT0WU
HCC1569	Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrG[ZY1UUN3ME2yMlI1PTh\|IN88US=>	M3LRUnNCVkeHUh?=
D-283MED	M2XyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjmcJdKSzVyPUKuNlQ4QDJizszN	NW\2UYdWW0GQR1XS
J-RT3-T3-5	NFH0UYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJwMkWzOVEh\|ryP	M3v5cXNCVkeHUh?=
ATN-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\KeXJrUUN3ME2yMlM{ODh{IN88US=>	NYnTR5ptW0GQR1XS
HCC1954	M1rhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzSTWM2OD1{LkO0OFA5KM7:TR?=	M2TieXNCVkeHUh?=
SCC-15	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\sTWM2OD1{LkO5N\|EzKM7:TR?=	MV3TRW5ITVJ?
COLO-668	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3RR49KSzVyPUKuOFMzKM7:TR?=	NG\KToxUSU6JRWK=
LB373-MEL-D	NV35Z45VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXNPWJKSzVyPUKuOVQ3PzdizszN	NEHEbXVUSU6JRWK=
no-10	M2LyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJwNUS5OFch\|ryP	MWHTRW5ITVJ?
HT-1197	M13MNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7yNlZKSzVyPUKuOlMyQDhizszN	NXTnSml7W0GQR1XS
DU-145	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfINlhsUUN3ME2yMlc6OTZ{IN88US=>	MmHEV2FPT0WU
SK-N-AS	NEH0XXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTvTWM2OD1{Lki0OlkzKM7:TR?=	NFLRbItUSU6JRWK=
MOLT-4	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvnSFFKSzVyPUKuPFU{OjJizszN	MWDTRW5ITVJ?
EW-22	NVqwOoNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnQTWM2OD1{LkmyPFQyKM7:TR?=	NXXJdms{W0GQR1XS
DB	NH2wSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTJwOUe3OVkh\|ryP	NUW1U2o5W0GQR1XS
HL-60	NXG4Z\|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fOOGlEPTB;Mz6wOFM4PiEQvF2=	NIrmWnBUSU6JRWK=
SK-N-DZ	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIOzT5lKSzVyPUOuNFUxPzVizszN	NVvIc5oxW0GQR1XS
NY	NH;NOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfrTJl1UUN3ME2zMlA5PTR{IN88US=>	NFnoVmlUSU6JRWK=
T47D	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzUTWM2OD1\|LkGwOVU5KM7:TR?=	MXXTRW5ITVJ?
NCI-H2029	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\wTWM2OD1\|LkKyOFc4KM7:TR?=	NGnrbGVUSU6JRWK=
KARPAS-299	M2Lte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTlb4t6UUN3ME2zMlI3ODJ5IN88US=>	MWnTRW5ITVJ?
KM-H2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2joZWlEPTB;Mz6zNFY5KM7:TR?=	MoTKV2FPT0WU
CHP-134	NHPoOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETwS2tKSzVyPUOuOFc{QSEQvF2=	MWDTRW5ITVJ?
22RV1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jUNWlEPTB;Mz60PVE3QCEQvF2=	M4HFRnNCVkeHUh?=
NB5	NH;ZWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LKWmlEPTB;Mz61NFY5QSEQvF2=	M1LUbHNCVkeHUh?=
CW-2	NHLCdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjkTndRUUN3ME2zMlU2OzF2IN88US=>	MXTTRW5ITVJ?
EFO-21	NH7BbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;X[mRKSzVyPUOuOVY6PCEQvF2=	MVfTRW5ITVJ?
HuH-7	NUe2VXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzOd2J2UUN3ME2zMlU5PDF2IN88US=>	Mo[wV2FPT0WU
ALL-PO	NFv0O4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTNwNkKzN\|Uh\|ryP	NInKbo1USU6JRWK=
EM-2	M3LScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkG0TWM2OD1\|Lk[5NFEyKM7:TR?=	NFe1eZlUSU6JRWK=
KLE	NXPFNHZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGexOZJKSzVyPUOuO\|MxOjlizszN	MnTNV2FPT0WU
NEC8	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTNwOUG4NFgh\|ryP	NHP5RpNUSU6JRWK=
KP-N-YN	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfrTWM2OD1\|LkmzOFc3KM7:TR?=	M4rtXHNCVkeHUh?=
SK-MEL-1	NEOxVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{O2fWlEPTB;ND6wN\|UyQCEQvF2=	NUXoSohWW0GQR1XS
CAL-54	M4fwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHRTWM2OD12LkC1PVEh\|ryP	MVzTRW5ITVJ?
MS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGP0eVhKSzVyPUSuNVYyPTVizszN	M4DoenNCVkeHUh?=
NCI-H209	M3\HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXuWo1KSzVyPUSuNlk6QTlizszN	MmnZV2FPT0WU
NOMO-1	NFvVWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGH5[VhKSzVyPUSuN\|IyOzFizszN	NXLEeJBYW0GQR1XS
RPMI-2650	NHjocVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm5WFdOUUN3ME20MlM3OzJ5IN88US=>	MVPTRW5ITVJ?
NCI-H810	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G1XGlEPTB;ND6zPVc{PiEQvF2=	MVvTRW5ITVJ?
Ca9-22	M4TaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTRwNEW2PVEh\|ryP	NEHVe3NUSU6JRWK=
ES4	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDIO5JKSzVyPUSuOFcxQTVizszN	NIn1bIFUSU6JRWK=
ES6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr6TWM2OD12LkS5OlU4KM7:TR?=	M3TveXNCVkeHUh?=
DMS-114	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTRwNUS2PVEh\|ryP	NXrXeXdDW0GQR1XS
ONS-76	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXJTWM2OD12LkW3PVUh\|ryP	MWrTRW5ITVJ?
K-562	NEHhcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XtRmlEPTB;ND63N\|gyPCEQvF2=	NGKwV\|hUSU6JRWK=
MHH-NB-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Cx[GlEPTB;ND63OVQ3OSEQvF2=	MlPrV2FPT0WU
Calu-3	NFTFV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTRwN{i1OFgh\|ryP	NYTWXFhyW0GQR1XS
HT55	NEixdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTRwOES1OFUh\|ryP	M{Lqd3NCVkeHUh?=
SK-N-FI	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrpcXJKSzVyPUSuPFUxODlizszN	M4S2RXNCVkeHUh?=
ES1	MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHxUVZpUUN3ME20Mlg3ODV5IN88US=>	NEnmT2ZUSU6JRWK=
SF126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTRwOUOxPFQh\|ryP	MWjTRW5ITVJ?
ES5	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DYN2lEPTB;NT6xNlQzPyEQvF2=	M{HlSnNCVkeHUh?=
LoVo	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LzV2lEPTB;NT6xOVg4OSEQvF2=	M{nQR3NCVkeHUh?=
SNU-387	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTVwM{KzN\|kh\|ryP	NYS5O5c1W0GQR1XS
C8166	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTVwM{[zN\|kh\|ryP	NUfHTG17W0GQR1XS
LS-1034	M1XGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n0NGlEPTB;NT60NlMxPyEQvF2=	NXL3eVJWW0GQR1XS
GR-ST	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\FTWM2OD13LkWyNlAyKM7:TR?=	M3f3ZnNCVkeHUh?=
NCI-H1092	NG\NbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPaT2NjUUN3ME21MlczQDR\|IN88US=>	NHjB[WdUSU6JRWK=
647-V	NF7QcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PaN2lEPTB;NT63OFcxPiEQvF2=	MUfTRW5ITVJ?
EW-13	NUXKcHdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHnTWM2OD13Lke2OlI4KM7:TR?=	M1HaW3NCVkeHUh?=
KGN	M3npd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{iwVmlEPTB;Nj6wPVkzOSEQvF2=	NYHvVFBUW0GQR1XS
D-423MG	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPOTWM2OD14LkSwNlg1KM7:TR?=	NXm5VW1uW0GQR1XS
ECC10	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3vTWM2OD15LkGwNVAyKM7:TR?=	Mo\BV2FPT0WU
TE-5	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTTe3hKSzVyPUeuOFEzQThizszN	M2THcHNCVkeHUh?=
P12-ICHIKAWA	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rQXmlEPTB;Nz60OVUzOyEQvF2=	NFjL[VBUSU6JRWK=
NCI-H82	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTdwNEW3NFEh\|ryP	MUDTRW5ITVJ?
NCI-H1993	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nOUWlEPTB;Nz64N\|A3OyEQvF2=	NH3UNYdUSU6JRWK=
RH-1	NHTBdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDzb\|Z[UUN3ME23Mlg2OjR2IN88US=>	MmTjV2FPT0WU
SW948	NHTjRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTdwOU[wOFkh\|ryP	MXnTRW5ITVJ?
CAL-33	NGKwb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLy[XdKSzVyPUeuPVk6OzhizszN	NWOydnlQW0GQR1XS
U-266	NUfCW4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW5cZRXUUN3ME24MlE2Pzd5IN88US=>	M133c3NCVkeHUh?=
CAL-72	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTKZ\|BHUUN3ME24MlIxOzJizszN	NY\OW5VHW0GQR1XS
SNU-423	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfiZWE4UUN3ME25MlM3PjZ4IN88US=>	MV7TRW5ITVJ?
KG-1	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTlwNUi0OVYh\|ryP	NXniOYU{W0GQR1XS
HCC1395	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPrTWM2OD17LkmyN\|UzKM7:TR?=	MXPTRW5ITVJ?
BE-13	M3j5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PDWWlEPTB;MUCuPFg6OiEQvF2=	NIHZU2FUSU6JRWK=
MKN7	NGK0NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLqTWM2OD1zMD65O\|Y2KM7:TR?=	MnixV2FPT0WU
697	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDHTWM2OD1zMT6xOFczKM7:TR?=	MV3TRW5ITVJ?
LU-135	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFzLkKzNFch\|ryP	NG\jRodUSU6JRWK=
ES7	M3LSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXKTWM2OD1zMT6zN\|E{KM7:TR?=	M1f5cnNCVkeHUh?=
SK-HEP-1	NVf1VVAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fz[2lEPTB;MUGuO\|Y1PiEQvF2=	NYjGfZlRW0GQR1XS
BEN	NVjISFJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTFzLki1NUDPxE1?	M1jDVXNCVkeHUh?=
NCI-H1770	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnT2TWM2OD1zMj6xNlYh\|ryP	NUDOfFRIW0GQR1XS
SW13	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\ENXBKSzVyPUGyMlE2PDFizszN	M3G4bXNCVkeHUh?=
MZ1-PC	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTF{LkW0OVIh\|ryP	NGDtdJpUSU6JRWK=
Mo-T	NYfLWG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkexTWM2OD1zMj63OFIyKM7:TR?=	NHz6OnBUSU6JRWK=
HLE	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTLZnRKSzVyPUGyMlgzOTVizszN	Ml3PV2FPT0WU
RCC10RGB	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTF\|Lk[3NUDPxE1?	NUPJZ4tyW0GQR1XS
COLO-320-HSR	NUXpS3p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFv3RlVKSzVyPUGzMlc{QDFizszN	NH3jdYJUSU6JRWK=
BHT-101	M3HlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjaR5hUUUN3ME2xN{45OzR3IN88US=>	NIXXOnNUSU6JRWK=
OCUB-M	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTF2LkG2NFIh\|ryP	M1nTWXNCVkeHUh?=
MEG-01	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTF2LkO3NFgh\|ryP	MoLTV2FPT0WU
RS4-11	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe0N2loUUN3ME2xOE44PDJizszN	MULTRW5ITVJ?
MN-60	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWCzVms1UUN3ME2xOE44QDl2IN88US=>	MYrTRW5ITVJ?
NCI-H1304	NEK3cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7WRpV[UUN3ME2xOU4xPDJ3IN88US=>	NWjte4pLW0GQR1XS
Ramos-2G6-4C10	M33q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zXPWlEPTB;MUWuNFU5OSEQvF2=	MnjVV2FPT0WU
NCI-H2342	NICxTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHjTWM2OD1zNT6yNFQ1KM7:TR?=	Ml;qV2FPT0WU
LAN-6	NGnRdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXmRmc4UUN3ME2xOU41PDF2IN88US=>	NFHOTIVUSU6JRWK=
JVM-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PpWWlEPTB;MUWuOVc1QCEQvF2=	MkTqV2FPT0WU
P30-OHK	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fBNWlEPTB;MU[uNFYyPCEQvF2=	M1rwW3NCVkeHUh?=
C-33-A	NXrTdYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkG3TWM2OD1zNj62NlE1KM7:TR?=	M{XGfHNCVkeHUh?=
RPMI-8866	NH:2RZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLqRoIxUUN3ME2xOk45PDl4IN88US=>	M4S3RnNCVkeHUh?=
NCI-H630	M4PkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrwTWM2OD1zNj64OVM4KM7:TR?=	Mof4V2FPT0WU
KYSE-140	M3\VXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFK1T5dKSzVyPUG3MlIxOjhizszN	M1P6VHNCVkeHUh?=
T84	NFLxVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjP[op4UUN3ME2xPE45Pjl3IN88US=>	MnjQV2FPT0WU
KU-19-19	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTw[VZIUUN3ME2xPE46PjB6IN88US=>	M4Hlc3NCVkeHUh?=
BALL-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\nTWM2OD1zOT6zN\|k6KM7:TR?=	M2nYbXNCVkeHUh?=
Calu-6	M4DIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzSV3RKSzVyPUG5MlQ6OiEQvF2=	MoXDV2FPT0WU
EGI-1	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXpemtKSzVyPUG5MlU6QCEQvF2=	M1;mPXNCVkeHUh?=
MFH-ino	NHq1T5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHmWZlKSzVyPUG5Mlc1PTRizszN	MkXtV2FPT0WU
GB-1	NF\3WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTJyLkO1N\|Uh\|ryP	M4jve3NCVkeHUh?=
NCI-H1693	M{DmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXJS5hKSzVyPUKwMlY2ODVizszN	Mn7zV2FPT0WU
SW1116	M37mVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTJyLkmzOlIh\|ryP	NGG3TppUSU6JRWK=
H-EMC-SS	M3P0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLNTWM2OD1{Mj6wOFUh\|ryP	NFrpenBUSU6JRWK=
D-502MG	M4Ttc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\6TWM2OD1{Mj64NlYyKM7:TR?=	NHToNYNUSU6JRWK=
IA-LM	M4naUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTFUXA2UUN3ME2yN{4zPDl\|IN88US=>	NUWye2VGW0GQR1XS
SW1463	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHCe\|NKSzVyPUKzMlc6KM7:TR?=	MVXTRW5ITVJ?
JAR	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\3PFhLUUN3ME2yOE4{Ojl\|IN88US=>	MX7TRW5ITVJ?
HT	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrISoU1UUN3ME2yOE41PzV\|IN88US=>	MYjTRW5ITVJ?
LCLC-103H	NFTlS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzXSnYxUUN3ME2yOE45PDR7IN88US=>	NFfYemhUSU6JRWK=
SNU-449	M3LwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYOx[\|lLUUN3ME2yOE45PzRzIN88US=>	MnzYV2FPT0WU
KE-37	M3XLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTJ3LkC5Nlgh\|ryP	NVnoTlE4W0GQR1XS
NCI-H1623	M3;6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofxTWM2OD1{Nz6xN\|A{KM7:TR?=	M2r3TXNCVkeHUh?=
MOLT-13	MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTJ5LkO1NVYh\|ryP	NX6wWG1uW0GQR1XS
COLO-741	NX7vcI1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXzeWxKSzVyPUOxMlM{OzNizszN	NWPlTFRnW0GQR1XS
NB6	M1XmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGW3cpVKSzVyPUOyMlI5PzZizszN	NHzlZYVUSU6JRWK=
MOLT-16	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfvW3BqUUN3ME2zN{4xODV3IN88US=>	Mn3MV2FPT0WU
IST-MES1	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTN2LkC1OFEh\|ryP	MlvUV2FPT0WU
A4-Fuk	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrvN4diUUN3ME2zOU4xPjZizszN	MnvSV2FPT0WU
CAL-85-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonpTWM2OD1\|NT6yPFE4KM7:TR?=	NVTqbWw5W0GQR1XS
CCRF-CEM	MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTN5LkG1N\|Yh\|ryP	MV\TRW5ITVJ?
HAL-01	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moj1TWM2OD1\|OD60PFg6KM7:TR?=	M13EXHNCVkeHUh?=
HEL	NEfFZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLETVNpUUN3ME20N{4{PDB7IN88US=>	M1Lrc3NCVkeHUh?=
EW-1	M3exSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFK5bWNKSzVyPUSzMlQ4PjhizszN	M4LHNnNCVkeHUh?=
MDA-MB-231	NFj4fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTR3LkGxPVkh\|ryP	NUPkOnRlW0GQR1XS
ABC-1	NF3ucJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXrTWM2OD12Nj64OVM5KM7:TR?=	NGDI[o9USU6JRWK=
NCI-H446	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fVU2lEPTB;NEiuOVA2QCEQvF2=	Mn\rV2FPT0WU
MHH-PREB-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTR7Lk[wNFch\|ryP	M2PNS3NCVkeHUh?=
DOHH-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTpZ4hbUUN3ME20PU43PjV4IN88US=>	NEDwWZRUSU6JRWK=
GCT	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLGTWM2OD12OT62PVc3KM7:TR?=	NILVbpNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00514371	Completed	Multiple Myeloma	Bristol-Myers Squibb	August 2007	Phase 2\|Phase 3
NCT00779428	Completed	Advanced Malignancies	Bristol-Myers Squibb	July 2006	Phase 2
NCT00773344	Completed	Solid Tumors\|Breast Cancer	Bristol-Myers Squibb	December 2005	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)